Risk-benefit analysis for drotrecogin alfa (activated)

Roland M.H. Schein, Gary T. Kinasewitz

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

An analysis of risks and benefits is an important component of patient care. Drotrecogin alfa (activated), the first approved cogin (a class of recombinant human coagulation inhibitors), provides a clear example of a treatment that requires a careful risk-benefit analysis. Treatment with this novel compound has been shown to reduce significantly the risk of death in patients with sepsis and acute organ dysfunction (severe sepsis). However, the drug is a natural antithrombotic that can increase the risk of bleeding in recipients. We will discuss bleeding and other potential risks associated with drotrecogin alfa (activated) treatment, as well as the survival benefits seen with the use of this therapy in patients with severe sepsis.

Original languageEnglish (US)
Pages (from-to)S25-S38
JournalAmerican journal of surgery
Volume184
Issue number6 SUPPL. 1
DOIs
StatePublished - Dec 1 2002

    Fingerprint

ASJC Scopus subject areas

  • Surgery

Cite this